Preservation of compound integrity under degradation-inducing conditions
Held under heat, light, oxidation and pH stress, the stabilized compound retains its structure through the evaluation period.
Pharmaceutical Integrity
Platform
Two licensable engines. One holds the compound stable, the other proves what the material is and where it has been.
Two engines. One integrity platform.
Independently deployable capabilities with complementary value when integrated. Neither engine replaces the other.
Engine One
Botanical Stability & Targeted Delivery
Proprietary stabilization of isolated plant-derived compounds, preserving chemical integrity through handling, storage and formulation.
- Chemical integrity
- Holds the compound within defined specifications against oxidation, light, temperature and enzymatic degradation.
- Research comparability
- Reduces the input variability that complicates comparison across lots, sites and time.
- Commercial reliability
- Cuts the retesting, handling controls and uncertain usable life that add development work.
- Targeted delivery
- Delivery remains part of the architecture. No clinical absorption or pharmacokinetic claim is made from stability alone.
Engine Two
Botanical Integrity, Provenance & Traceability
Material-based identity verification and documented lifecycle continuity: source, handling and comparability over time.
- Material signature
- Captures intrinsic chemical characteristics of the compound itself through a non-destructive sensing approach.
- Reference and records
- Compares against qualified reference data and links documented source and handling events to the result.
- Verifiable continuity
- Supports identity, comparability, anomaly review and an auditable lifecycle record across custody changes.
- Anti-counterfeit and enforcement
- Verifies the material rather than the label, which is what counterfeiting, diversion and tax enforcement turn on.
Two core challenges limiting pharmaceutical success
Performance variability
Molecular instability
Inconsistent pharmacokinetics
Variable clinical outcomes
Difficulty in FDA study replication
Integrity and trust gaps
Counterfeit and diverted products
Lack of product-level verification
Undetected tampering or handling failures
Fragmented supply chain visibility
A unified approach
One licensing platform that resolves both challenges.
Two complementary engines, deployed independently or integrated, hold consistency from formulation through end use. Neither is a prerequisite for the other.
Four licensable layers across the two engines.
Each layer licenses on its own. Together they cover how a product performs and whether it can be trusted.
Stabilization: performance integrity.
Preserves molecular structure and function, for more predictable performance and less variability in clinical outcomes.
Track and trace: identity and provenance.
Verifies the material by its own chemical signature, for anti-counterfeiting, chain of custody, and enforcement in regulated supply chains.
Formulation: controlled delivery.
Carrier systems designed for controlled release, reproducible dosing, and manufacturing-ready scalability.
Precision Analytics: structured proof.
Compound integrity, active concentration, and carrier performance verified at every stage, so claims arrive with data.
Where each engine licenses.
The two engines reach different markets. Neither list is a subset of the other, which is why they license separately.
Engine One
Botanical Stability & Targeted Delivery
3 verticals
- Pharmaceuticals
- Food, Beverage and Nutraceuticals
- Cosmetics and Personal Care
Engine Two
Botanical Integrity, Provenance & Traceability
30 verticals
- Pharmaceutical supply chains
- Botanical-drug supply chains
- Cannabis and hemp
- Nutraceuticals and supplements
- Food and beverage
- Agriculture
- Seed genetics and certified seed
- Crop authentication
- Ingredient authentication
- Cosmetics and personal care
- Essential oils
- Herbal medicine
- Mycological products
- Veterinary products
- Agricultural biologicals
- Biofuel feedstocks
- Biomass commodities
- Textiles and natural fibers
- Hempcrete and building materials
- Lumber and plant-derived construction materials
- Government-regulated supply chains
- Customs and import-export verification
- Laboratory and research-chain integrity
- Clinical-trial material authentication
- Anti-counterfeiting
- Chain-of-custody systems
- ESG and sustainability verification
- Geographic-origin verification
- Cultivar, lineage and genetics verification
- Commodity trading and certification
Validation
Internal validation has demonstrated consistent and repeatable performance across controlled evaluation environments relevant to pharmaceutical applications.
Improved consistency in pharmacokinetic-related outcomes
Release and uptake behavior stays within a tighter band across repeat runs rather than varying batch to batch.
Reliable detection of controlled inconsistencies in product identity
Deliberately altered and substituted units were identified at the product level during controlled evaluation.
Repeatable system behavior across varied test conditions
The same result holds when conditions, operators and equipment change, which is what makes the method transferable.
Maintained biological performance over extended timeframes
Functional activity is preserved across extended timepoints, not only at the moment of formulation.
Performance + Trust Across the Lifecycle
Run together, the two engines form one Pharmaceutical Integrity Platform addressing both core dimensions of pharmaceutical reliability. Run alone, each still does its own job in full.
End-to-end consistency
From formulation through end use, both performance and identity are maintained.
Reduced variability
Engine One reduces input variability while Engine Two reduces supply chain and counterfeit risk.
Increased confidence
Partners and regulators gain confidence in both what the product does and what it is.
Request technical materials.
Detailed technical information, validation data, and platform architecture are available under appropriate confidentiality agreements.
Platform questions
Yes. Each is independently deployable and licenses on its own. Engine One can be licensed for a drug development program alone. Engine Two can be deployed across manufacturing, distribution and regulated supply chains alone.
Integrated, they cover both what a product does and what it is. Engine One reduces the variability that undermines performance, Engine Two removes the doubt about identity and origin, and together they hold consistency from formulation through end use.
Internal validation has demonstrated preservation of compound integrity under degradation-inducing conditions, improved consistency in pharmacokinetic-related outcomes, reliable detection of controlled inconsistencies, and repeatable system behavior across varied test conditions.
Detailed technical information, validation data, and platform architecture are available under appropriate confidentiality agreements. Use the Contact page to request access.